Video Experimental Relacionado
Updated: May 5, 2026
07:46
Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung
Published on: June 5, 2012
34.5K
Azitromicina en pacientes con fibrosis quística infectados crónicamente con Pseudomonas aeruginosa: un ensayo
Lisa Saiman1, Bruce C Marshall, Nicole Mayer-Hamblett
1Department of Pediatrics, Columbia University College of Physicians and Surgeons, New York, NY 10032-3784, USA. ls5@columbia.edu
JAMA
|October 2, 2003
Resumen
La azitromicina mejoró la función pulmonar y redujo las exacerbaciones en pacientes con fibrosis quística. Este antibiótico macrólido ofrece una posible opción de tratamiento para las personas con infecciones crónicas por Pseudomonas aeruginosa.
Área de la Ciencia:
- Pulmonología Pulmonología.
- Enfermedades infecciosas Enfermedades infecciosas.
- Farmacología Farmacología.
Sus antecedentes:
- El tratamiento de la enfermedad pulmonar de la fibrosis quística (FQ) incluye antibióticos, mucolíticos y antiinflamatorios.
- Los antibióticos macrolides muestran beneficios potenciales para los pacientes con FQ.
Objetivo del estudio:
- Investigar la asociación entre el uso de azitromicina y la función pulmonar en pacientes con fibrosis quística (FQ).
- Evaluar la eficacia y seguridad de la azitromicina en pacientes con FQ con infección crónica por Pseudomonas aeruginosa.
Principales métodos:
- Un ensayo multicéntrico, aleatorizado, doble ciego, controlado con placebo.
- 185 pacientes con FQ (edad ≥6 años, infección por P. aeruginosa, FEV1 ≥30%) recibieron azitromicina oral o placebo durante 168 días.
- Resultado primario: cambio en el FEV1; resultados secundarios: exacerbaciones pulmonares y aumento de peso.
Principales resultados:
- El grupo de azitromicina mostró un aumento significativo en el FEV1 (0,097 L frente a 0,003 L, P = 0,009).
- Se observó una reducción del riesgo de exacerbaciones pulmonares (HR = 0,65, P = 0,03) y un aumento del aumento de peso (0,7 kg, P = 0,02) en el grupo de azitromicina.
- Se informó un aumento de la incidencia de náuseas, diarrea y sibilancias en el grupo de azitromicina.
Conclusiones:
- El tratamiento con azitromicina está relacionado con mejores resultados clínicos en pacientes con FQ.
- Considere la azitromicina para pacientes con FQ (≥6 años) con infección crónica por P. aeruginosa.
- La azitromicina demuestra un perfil de riesgo-beneficio favorable en esta población de pacientes.
Más Videos Relacionados
Videos de Conceptos Relacionados
01:19Antiasthma Drugs: Leukotriene Modifiers
2.2K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.2K
01:23Cystic Fibrosis: Pathogenesis
1.1K
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
1.1K
01:24Cystic Fibrosis: Management
657
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
657
01:28Pulmonary Tuberculosis V
1.0K
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
1.0K
01:30Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
440
A healthcare provider can diagnose a urinary tract infection (UTI) through several methods:Medical History and Symptoms: The provider will take a detailed medical history and ask about symptoms such as frequent urination, burning sensation during urination, and lower abdominal pain.Urinalysis: A clean-catch urine sample is collected in a sterile container and tested for the presence of bacteria, white blood cells (leukocytes), nitrites, blood, and protein. The presence of leukocytes and...
440